Shenzhen Shenxin Biotechnology Co., Ltd

This study tests a new mRNA vaccine called IN006 to see if it is safe and helps the immune system fight respiratory syncytial virus (RSV) in healthy adults aged 60 and older. About 500 participants will receive either the vaccine or a placebo, and researchers will monitor side ef…

This early-stage study tests a new mRNA vaccine (IN006) designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo to check for side …